Coronavirus puts on hold launch plans for Neurocrine's Parkinson's drug

Neurocrine Biosciences, a San Diego-based medicine company, expects to receive approval this weekend for a drug that makes a prominent Parkinson's disease treatment last longer. Patients in the United States, though, wouldn't have access to the drug for at least another couple months, as Neurocrine intends to hold off any launch because of coronavirus-related concerns.